King Rachel K.'s Insider Trades & SAST Disclosures
King Rachel K.'s most recent trade in Novavax, Inc. was a trade of 4,150 Common Stock done at an average price of $9.0 . Disclosure was reported to the exchange on Dec. 13, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern King Rachel K..To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Novavax, Inc. | Rachel K. King | Director | Sale of securities on an exchange or to another person at price $ 9.02 per share. | 13 Dec 2024 | 4,150 | 14,770 (0%) | 0% | 9.0 | 37,435 | Common Stock |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 15,630 | 15,630 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 10,420 | 10,420 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Rachel K. King | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,670 | 18,920 (0%) | 0% | 0 | Common Stock | |
| Novavax, Inc. | Rachel K. King | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2024 | 6,670 | 0 | - | - | Restricted Stock Units | |
| GlycoMimetics Inc | Rachel K. King | Director | 01 May 2024 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | ||
| GlycoMimetics Inc | King Rachel K. | Director | 29 Dec 2023 | 4,238 | 511,860 (1%) | 0% | 2.4 | 10,002 | Common stock | |
| GlycoMimetics Inc | Rachel K. King | Director | 30 Sep 2023 | 6,667 | 507,622 (1%) | 0% | 1.5 | 10,001 | Common stock | |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2023 | 7,710 | 7,710 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2023 | 6,670 | 6,670 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Rachel K. King | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 3,100 | 10,050 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Rachel K. King | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2023 | 3,100 | 0 | - | - | Restricted Stock Units | |
| GlycoMimetics Inc | Rachel K. King | Director | 19 May 2023 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | ||
| GlycoMimetics Inc | Rachel K. King | Director | 29 Mar 2023 | 3,334 | 515,194 (1%) | 0% | 3 | 10,002 | Common Stock | |
| GlycoMimetics Inc | Rachel K. King | Director | 31 Dec 2022 | 11,641 | 500,955 (1%) | 0% | 0 | Common Stock | ||
| GlycoMimetics Inc | Rachel K. King | Director | 31 Dec 2022 | 7,500 | 7,500 (0%) | 0% | 0 | Common Stock | ||
| Novavax, Inc. | Rachel K. King | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 700 | 0 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Rachel K. King | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 700 | 6,950 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 4,600 | 4,600 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2022 | 3,100 | 3,100 | - | - | Restricted Stock Units | |
| GlycoMimetics Inc | Rachel K. King | Director | 18 May 2022 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | ||
| Novavax, Inc. | Rachel K. King | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2021 | 3,450 | 3,450 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Rachel K. King | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2021 | 3,450 | 6,250 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 1,300 | 1,300 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 700 | 700 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Rachel K. King | Director | Purchase of securities on an exchange or from another person at price $ 139.64 per share. | 19 May 2021 | 700 | 2,800 (0%) | 0% | 139.6 | 97,748 | Common Stock |
| GlycoMimetics Inc | Rachel K. King | Director, President, CEO | 20 Jan 2021 | 192,500 | 192,500 | - | - | Employee Stock Option (right to buy) | ||
| GlycoMimetics Inc | Rachel K. King | Director, President, CEO | 20 Jan 2021 | 96,250 | 452,314 (1%) | 0% | 0 | Common Stock | ||
| GlycoMimetics Inc | Rachel K. King | Director, President, CEO | 28 Dec 2020 | 130,821 | 440,240 (1%) | 0% | 1.1 | 146,520 | Common Stock | |
| GlycoMimetics Inc | Rachel K. King | Director, President, CEO | 28 Dec 2020 | 130,821 | 0 | - | - | Employee Stock Option (right to buy) | ||
| GlycoMimetics Inc | Rachel K. King | Director, President, CEO | 28 Dec 2020 | 84,176 | 356,064 (0%) | 0% | 3.9 | 329,128 | Common Stock | |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 6,900 | 6,900 | - | - | Stock Option (Right to buy) | |
| Novavax, Inc. | Rachel K. King | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 3,450 | 3,450 | - | - | Restricted Stock Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges